Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …

Background COVID-19 disproportionately results in hospitalization and death in older
patients and those with underlying comorbidities. Sotrovimab is a pan-sarbecovirus …

Abstract Background Coronavirus disease 2019 (Covid-19) disproportionately results in
hospitalization or death in older patients and those with underlying conditions. Sotrovimab is …

Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …

Dear Editor, We read with great interest the article in this journal by Luo et al. regarding the
use of tocilizumab in patients with COVID-19 infection 1. As the global cases of COVID-19 …

Abstract Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody
targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a …

The therapeutic potential of sotrovimab in the treatment of coronavirus disease 2019 (COVID‐
19) is a controversial issue. The aim of this study was to evaluate the efficacy and safety of …

(1) Introduction: Since May 2021, sotrovimab has been available in Italy for early treatment
of SARS-CoV-2 infection and to prevent disease progression. However, some in vitro …

Aim: Sotrovimab, an engineered human monoclonal antibody, targets a conserved region of
the SARS-CoV-2 spike protein. The phase III COMET-TAIL study evaluated noninferiority of …

Aim: Sotrovimab is an engineered human monoclonal antibody that binds a conserved
region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated …